Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer.
These findings establish METTL14 as a central pharmacological target whose inhibition suppresses the Wnt9a/β-catenin pathway, enhances radiotherapy and anti-PD-1 efficacy, and reduces CSC-driven progression in NSCLC.